Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866852 | 1.00 | MAOB (0.60) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5866768 | 0.88 | FADS1 (0.48) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5866770 | 0.88 | FADS1 (0.48) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5866763 | 0.87 | MAOB (0.56) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5866919 | 0.87 | MAPT (0.45) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5866920 | 0.87 | MAPT (0.45) | MAOBNPC1RAB9AMAPTTP53 | |
| SCHEMBL5935550 | 0.79 | HTT (0.53) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL5935552 | 0.79 | HTT (0.53) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL5866934 | 0.78 | BCAT1 (0.47) | NPC1RAB9AMAPTTP53SMN1; SMN2 | |
| SCHEMBL5866846 | 0.78 | MEN1 (0.52) | MAOBNPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | AMGEN INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7053234-B2 | Antibacterial agents | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | TULARIK INC. | 2004-11-25 | — | — | US | disclosed |
| US-6780858-B2 | Antibacterial agents | TULARIK INC. | 2004-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235911-A1 | hydroxyamidines; antibiotic resistance | HNMT, HDHD5, ABCC1 | MAOB 876/4885NPC1 2881/4885RAB9A 941/4885 |
| US-20060270651-A1 | ANTIBACTERIAL AGENTS | MRPL21, HDHD5, CLPP | MAOB 1286/4885NPC1 2994/4885RAB9A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.